Loading...
Intravenous iron is commonly used to correct iron deficiency anemia in patients with inflammatory bowel disease (IBD). Prior studies have demonstrated its greater efficacy, tolerability, and quality-of-life improvement compared with oral iron therapy. Now, investigators have tested the efficacy and safety of an alternative intravenous regimen — ferric carboxymaltose (FCM) — against standard intravenous iron sucrose (IS) therapy.
In an industry-sponsored, randomized, controlled, multicenter trial, researchers randomized 485 patients with IBD and iron deficiency anemia to receive 1 to 3 weekly infusions of 500 or 1000 mg of FCM or 200 mg of IS up to twice weekly for a maximum of 11 infusions. The total (cumulative) dose of FCM was calculated u…